Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

被引:695
作者
Lutsiak, MEC
Semnani, RT
De Pascalis, R
Kashmiri, SVS
Schlom, J
Sabzevari, H
机构
[1] Ctr Canc Res, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA
[2] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1182/blood-2004-06-2410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Regulatory T cells (T-REGs) control the key aspects of tolerance and play a role in the lack of antitumor immune responses. Cyclophosphamide (CY) is a chemotherapeutic agent with a dose-dependent, bimodal effect on the immune system. Although a previous study demonstrated that CY reduces the number of T-REGs, the mechanism involved in this process has yet to be defined. In this report, it is established that low-dose CY not only decreases cell number but leads to decreased functionality of TREGS-CY treatment enhances apoptosis and decreases homeostatic proliferation of these cells. Expression of GITR and FoxP3, which are involved in the suppressive activity of T-REGs, is down-regulated after CY administration, though the level of expression varies depending on the time studied. This is the first report demonstrating that CY, in addition to decreasing cell number, inhibits the suppressive capability of T-REGS. The relevance of the loss of suppressor functionality and the changes in gene expression are further discussed.
引用
收藏
页码:2862 / 2868
页数:7
相关论文
共 36 条
  • [1] Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease:: a long-term follow-up
    Aschan, J
    Carlens, S
    Hägglund, H
    Klaesson, S
    Mattsson, J
    Remberger, M
    [J]. CLINICAL TRANSPLANTATION, 1999, 13 (06) : 512 - 519
  • [2] Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse
    Brunkow, ME
    Jeffery, EW
    Hjerrild, KA
    Paeper, B
    Clark, LB
    Yasayko, SA
    Wilkinson, JE
    Galas, D
    Ziegler, SF
    Ramsdell, F
    [J]. NATURE GENETICS, 2001, 27 (01) : 68 - 73
  • [3] Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells (Reprinted from vol 4, pg 330-336, 2003)
    Fontenot, Jason D.
    Gavin, Marc A.
    Rudensky, Alexander Y.
    [J]. JOURNAL OF IMMUNOLOGY, 2017, 198 (03) : 986 - 992
  • [4] Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivo
    Gavin, MA
    Clarke, SR
    Negrou, E
    Gallegos, A
    Rudensky, A
    [J]. NATURE IMMUNOLOGY, 2002, 3 (01) : 33 - 41
  • [5] CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
    Ghiringhelli, F
    Larmonier, N
    Schmitt, E
    Parcellier, A
    Cathelin, D
    Garrido, C
    Chauffert, B
    Solary, E
    Bonnotte, B
    Martin, F
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (02) : 336 - 344
  • [6] AUGMENTATION OF SPECIFIC IMMUNE-RESPONSE AGAINST A SYNGENEIC SV40-INDUCED SARCOMA IN MICE BY DEPLETION OF SUPPRESSOR T-CELLS WITH CYCLOPHOSPHAMIDE
    GLASER, M
    [J]. CELLULAR IMMUNOLOGY, 1979, 48 (02) : 339 - 345
  • [7] Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR
    Gurney, AL
    Marsters, SA
    Huang, A
    Pitti, RM
    Mark, M
    Baldwin, DT
    Gray, AM
    Dowd, P
    Brush, J
    Heldens, S
    Schow, P
    Goddard, AD
    Wood, WI
    Baker, KP
    Godowski, PJ
    Ashkenazi, A
    [J]. CURRENT BIOLOGY, 1999, 9 (04) : 215 - 218
  • [8] Control of regulatory T cell development by the transcription factor Foxp3
    Hori, S
    Nomura, T
    Sakaguchi, S
    [J]. SCIENCE, 2003, 299 (5609) : 1057 - 1061
  • [9] Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients
    Itescu, S
    Burke, E
    Lietz, K
    John, R
    Mancini, D
    Michler, R
    Rose, E
    Oz, M
    Edwards, N
    [J]. CIRCULATION, 2002, 105 (10) : 1214 - 1219
  • [10] Itoh M, 1999, J IMMUNOL, V162, P5317